FPH.NZ - Fisher & Paykel Healthcare Corporation Limited
| Previous close | 15.30 |
| Open | 15.25 |
| Bid | 15.05 x 485800 |
| Ask | 15.30 x 241000 |
| Day's range | 15.00 - 15.32 |
| 52-week range | 11.92 - 16.44 |
| Volume | 706,521 |
| Avg. volume | 668,541 |
| Market cap | 8.734B |
| Beta | 1.68 |
| PE ratio (TTM) | 46.24 |
| EPS (TTM) | 0.33 |
| Earnings date | 26 Nov 2018 |
| Forward dividend & yield | 0.25 (1.65%) |
| Ex-dividend date | 2018-06-21 |
| 1y target est | 12.79 |
- Simply Wall St.•3 days ago
Why Fundamental Investors Might Love Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
I’ve been keeping an eye on Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stockRead More...
- Simply Wall St.•22 days ago
Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Attractive At Its Current PE Ratio?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
- Simply Wall St.•3 months ago
Top Growth Stocks To Buy Today
Robust, high-growth companies such as NZX are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed to financiallyRead More...
- Simply Wall St.•3 months ago
June Fundamental Stock Pick: Fisher & Paykel Healthcare Corporation Limited (NZE:FPH)
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) due to its excellentRead More...
- AAP•10 months ago
Fisher & Paykel wins patent court case
Fisher & Paykel Healthcare has won a patent case against rival medical products manufacturer ResMed, after a court in the United Kingdom ruled the patent claim invalid. In 2016, New Zealand-based Fisher & Paykel sought a declaration from the High Court that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed revoked two of its patents in the UK just before the trial was due to start, but left one for consideration by the High Court's patents division.
